Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome
NCT00001145Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 1999
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of rhuCD40L in X-linked hyper IgM syndrome (X-HIGM), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 1999; status: completed.
02
Drugs
rhuCD40L
03
Conditions
X-linked hyper IgM syndrome (X-HIGM)
Beyond the preview
Go deeper on NCT00001145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001145.